Japan Approved VYJUVEK

It will be a life saver when Pharmac approve this in NZ.

Krystal Biotech’s VYJUVEK has been approved by Japan’s Ministry of Health, Labour and Welfare for the treatment of wounds caused by dystrophic epidermolysis bullosa (DEB).

This is the first genetic therapy authorised in Japan for DEB. The therapy can be administered either in healthcare facilities or at home by patients or their families.

The launch of VYJUVEK is expected by the end of 2025  Read more on the DEBRA International website  https://www.debra-international.org/.../japan-receives...